Stacy E. Croteau, MD, MMS, Steven W. Pipe, MD - Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategies in Hemophilia A

Go online to PeerView.com/SFD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new PeerView activity based on a recorded symposium at the 75th Annual Bleeding Disorders Conference, an expert panel engages in thought-provoking, interactive case-based discussions and offers guidance on how healthcare professionals can address real-world challenges of hemophilia A management with novel EHL FVIII prophylaxis. Our experts provide guidance on critically evaluating the latest clinical evidence, tailoring treatment plans to individual patient needs, and navigating the challenges associated with patient adherence, access to therapy, and transitioning patients from conventional options (eg, SHL FVIII replacement therapy) to innovative EHL FVIII prophylaxis. Access this activity now to see if you are prepared to lead the way to better outcomes for hemophilia A! Upon completion of this activity, participants should be better able to: Summarize the mechanistic differences and latest clinical evidence with novel EHL FVIII replacement agents for hemophilia A; Identify unmet medical needs and barriers to optimal prophylaxis of hemophilia A; Integrate novel EHL FVIII replacement therapies into personalized treatment regimens for patients with hemophilia A based on clinically-relevant factors, current evidence, and guideline recommendations, among other considerations; and Develop strategies to address practical aspects of care, such as dosing, safety considerations, monitoring, patient education, and adherence counseling, when using novel EHL FVIII agents